Navigation Links
Experimental Vitiligo Treatment Shows Promise in Mice
Date:2/27/2013

WEDNESDAY, Feb. 27 (HealthDay News) -- A genetically modified protein could provide the first effective treatment for the skin condition vitiligo, a new study in mice suggests.

People with vitiligo have white patches on the face, hands and other parts of the body. Vitiligo is an autoimmune disorder in which the immune system becomes overactive and kills the pigment cells that give skin its color.

Researchers at the Loyola University Chicago Stritch School of Medicine developed a genetically modified protein that reversed vitiligo in mice and had similar effects on human skin tissue samples. Findings from animal studies do not always hold up in human trials, however.

A protein called HSP70i plays a major role in the autoimmune response that causes vitiligo. The researchers genetically modified an amino acid in the protein in order to create a mutant version of HSP70i. This version replaces normal HSP70i and reverses the autoimmune response that causes vitiligo, the study authors explained in a Loyola news release.

When the mutant HSP70i was given to mice with vitiligo, their salt-and-pepper fur turned black, giving them a normal appearance. The mutant protein had a similar effect on human skin samples, according to the study, published in the current issue of the journal Science Translational Medicine.

Researcher I. Caroline Le Poole, a professor in Loyola's Oncology Institute, and colleagues are seeking approval and funding to conduct a clinical trial of the modified protein in humans.

About 1 million Americans have vitiligo, which affects about one in 200 people worldwide. There are no long-term effective treatments for the condition. Current options include steroid creams, light therapy and skin grafts, but none of them can prevent vitiligo from progressing.

More information

The U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases has more about vitiligo.

-- Robert Preidt

SOURCE: Loyola University Health System, news release, Feb. 27, 2013


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Harmful effects of bisphenol A proved experimentally
2. Experimental agent briefly eases depression rapidly in test
3. NIH-funded trial launched to assess experimental TB drug
4. Experimental graft-vs.-host disease treatment equivalent to standard care in Phase 3 trial
5. Experimental Antidepressant Appears Quick-Acting, Safe
6. More than a third of high-risk leukemia patients respond to an experimental new drug
7. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
8. Experimental Insomnia Drug Shows Promise
9. Experimental Dengue Vaccine Shows Some Success
10. Standard chemotherapy provides higher survival rate than experimental in lung cancer patients
11. Cancer turns off important immune cells, complicating experimental vaccine therapies
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Vitiligo Treatment Shows Promise in Mice
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Calif. , June 24, 2016  Global ... a biopharmaceutical company developing novel therapeutics for the ... needs, today announced the closing of its previously ... common stock, at the public offering price of ... the offering were offered by GBT. GBT estimates ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
Breaking Medicine Technology: